ARCHIVES

Ceritinib Demonstrates 58% ORR, 7-month PFS in ALK+ NSCLC

This article is from The Cancer Letter archive.

Vol. 37 No. 3 | March 28, 2014

Download PDF Visit The Full Archive

Related Articles

NCI Facing Extended Tie Under Acting Director – Maybe

August 19, 1988

Exercise May Help Combat Leukemia Patients’ Fatigue

August 28, 2009

Three Win Nobel Prize In Medicine; Irving Center Awarded $10M For Breast Cancer Research.

October 13, 2000

HPV DNA Testing Reduced Cervical Cancer Precursors

September 24, 2010

CCOPs, Research Base Awards Are Listed

November 19, 1993

Britain’s Cancer Czar Begins Examination of Risks and Benefits of Mammography

October 28, 2011